Abstract:Parkinson's disease (PD) is characterized by divergent clinical symptoms and prognosis, suggesting the presence of distinct subtypes. Identifying these subtypes is crucial for understanding the underlying pathophysiology, predicting disease progression, and developing personalized treatments. In this study, we propose a connectivity-based subtyping approach, which measures each patient's deviation from the reference structural covariance networks established in healthy controls. Using data from the Parkinson's Progression Markers Initiative, we identified two distinct subtypes of de novo PD patients: 248 patients with typical cortical-striato-thalamic dysfunctions and 41 patients showing weakened dorsal raphe nucleus (DRN)-to-cortical/striatal projections. The proposed subtyping approach demonstrated high stability in terms of random sampling of healthy or diseased population and longitudinal prediction at follow-up visits, outperforming the traditional motor phenotypes. Compared to the typical PD, patients with the DRN-predominant subtype were characterized by less server motor symptoms at baseline and distinct imaging biomarkers, including larger striatal volumes, higher concentration of cerebrospinal fluid amyloid-β and amyloid-β/t(p)-tau ratio. Subtype-specific associations and drug effects were identified that the DRN subtype exhibited more pronounced medication effects on motor symptoms, potentially regulated by DRN serotonergic modulation through striatal dopaminergic neurons. The DRN serotonergic inputs also regulated non-motor symptoms, the aggregation of CSF biomarkers and the conversion to more severe disease states. Our findings suggest that the DRN-predominant subtype represents a unique clinical and biological phenotype of PD characterized by an enhanced response to anti-parkinsonian treatment, more favorable prognosis and slower progression of dopamine depletion. This study may contribute to clinical practice of precision medicine, early invention and individualized treatments in PD and other neurodegenerative diseases.

Elucidating Molecular Networks Underpinning Heterogeneity in Parkinson’s Disease Progression Across Clinical Manifestation Spectrum

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Contrastive Machine Learning Reveals Parkinson’s Disease Specific Features Associated with Disease Severity and Progression

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Patient-centered Transcriptomic and Multimodal Neuroimaging Determinants of Clinical Progression, Physical Activity and Treatment Needs in Parkinson Disease

Connectivity-Based Subtyping of De Novo Parkinson Disease: Biomarkers, Medication Effects and Longitudinal Progression

Clinically relevant connectivity features define three subtypes of Parkinson's disease patients

Genome-wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in Parkinson’s Disease

Deciphering shared molecular dysregulation across Parkinson's disease variants using a multi-modal network-based data integration and analysis

Cohort-specific Boolean models highlight different regulatory modules during Parkinson’s disease progression

The Landscape of Multiscale Transcriptomic Networks and Key Regulators in Parkinson's Disease

Proteogenomic network analysis reveals dysregulated mechanisms and potential mediators in Parkinson's disease

Personalized Progression Modelling and Prediction in Parkinson’s Disease with a Novel Multi-Modal Graph Approach

Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.

Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression

An Integrative Network Approach for Longitudinal Stratification in Parkinson’s Disease

Identifying and Predicting Parkinson's Disease Subtypes through Trajectory Clustering via Bipartite Networks

Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies

Gene Co-Expression Network Analysis Implicates microRNA Processing in Parkinson's Disease Pathogenesis

Identification of Hub Genes And Potential Molecular Mechanisms In Peripheral Blood Mononuclear Cells of Patients With Parkinson’s Disease

Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits